▶ 調査レポート

性感染症(STD)治療薬の世界市場分析・規模・シェア・成長・動向・予測:疾患別、治療分類別

• 英文タイトル:Sexually Transmitted Diseases (STDs) Drug Market (Disease Type - Chlamydia, Gonorrhea, Syphilis, Genital herpes, HPV, and HIV / AIDS; Therapy Class- Antibiotics, Antiviral / Antiretrovirals, and Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Transparency Market Researchが調査・発行した産業分析レポートです。性感染症(STD)治療薬の世界市場分析・規模・シェア・成長・動向・予測:疾患別、治療分類別 / Sexually Transmitted Diseases (STDs) Drug Market (Disease Type - Chlamydia, Gonorrhea, Syphilis, Genital herpes, HPV, and HIV / AIDS; Therapy Class- Antibiotics, Antiviral / Antiretrovirals, and Vaccines) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 / TPM-B04292資料のイメージです。• レポートコード:TPM-B04292
• 出版社/出版日:Transparency Market Research / 2017年11月
• レポート形態:英文、PDF、293ページ
• 納品方法:Eメール
• 産業分類:製薬・医療
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、性感染症(STD)治療薬の世界市場について調べ、性感染症(STD)治療薬の世界規模、市場動向、市場環境、疾患別分析、治療分類別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・性感染症(STD)治療薬の世界市場動向
・性感染症(STD)治療薬の世界市場環境
・性感染症(STD)治療薬の世界市場規模
・性感染症(STD)治療薬の世界市場規模:疾患別
・性感染症(STD)治療薬の世界市場規模:治療分類別
・性感染症(STD)治療薬の世界市場:地域別市場規模・分析
・性感染症(STD)治療薬の北米市場規模・予測
・性感染症(STD)治療薬のアメリカ市場規模・予測
・性感染症(STD)治療薬の中南米市場規模・予測
・性感染症(STD)治療薬のヨーロッパ市場規模・予測
・性感染症(STD)治療薬のアジア市場規模・予測
・性感染症(STD)治療薬の日本市場規模・予測
・性感染症(STD)治療薬の中国市場規模・予測
・性感染症(STD)治療薬のインド市場規模・予測
・性感染症(STD)治療薬の中東市場規模・予測
・性感染症(STD)治療薬のアフリカ市場規模・予測
・競争状況・関連企業情報

Global Sexually Transmitted Diseases (STDs) Drugs: Overview
Sexually transmitted diseases (STDs), also referred as venereal diseases are infections that can pass from person to person during sex. These diseases are caused mainly due to bacteria, viruses, and / or parasites. Sexually transmitted diseases (STDs) often go undiagnosed because these infections usually do not exhibit visual symptoms. Chlamydia is a common sexually transmitted disease. It is caused by bacteria called Chlamydia trachomatis. It can infect both men and women. Gonorrhea is caused due to bacterial infection (bacterium Neisseria gonorrhoeae) that can be passed from one person to another during sex. The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.

Global Sexually Transmitted Diseases (STDs) Drugs: Trends and Opportunities

The global market for sexually transmitted diseases (STDs) drug is expanding significantly, owing to increased chances of infection led by increase in the life expectancy of people across the globe. Rise in incidences of unprotected sex has led to an increase in the prevalence of sexually transmitted diseases. A driving factor for the sexually transmitted diseases (STDs) drug is rising initiatives by governments and multiple agencies drawn up guidelines or recommendations for sexually transmitted diseases (STDs). Low voluntary screening rate for sexually transmitted diseases (STDs) is major restrain for this market.

Global Sexually Transmitted Diseases (STDs) Drugs: Segmentation

The global sexually transmitted diseases (STDs) drug market has been segmented on the basis of disease type, therapy class, distribution channel, and region. On the bases of disease type, sexually transmitted diseases (STDs) drug market can be further segmented into chlamydia, gonorrhea, syphilis, human papillomavirus infection, HIV/AIDS and others. According to therapy class sexually transmitted diseases (STDs) drug market can be segmented into antibiotics, antiviral, vaccines and others. Antiviral drugs are used in the treatment of lethal viral infections caused by viruses like human immunodeficiency virus (HIV), hepatitis, influenza A and B viruses and herpes viruses. Vaccination has been promoted as a vital public health intervention across the globe for decades. According to the World Health Organization (WHO), vaccination has reduced the global burden of infectious disease to a great extent. In terms of distribution channel, the sexually transmitted diseases (STDs) drug market can be segmented into hospitals pharmacies, retail pharmacies, online pharmacies and others. In terms of revenue, the hospitals segment held a significant share of the sexually transmitted diseases (STDs) drug market in 2016.

Global Sexually Transmitted Diseases (STDs) Drugs: Regional Outlook

Geographically, the global sexually transmitted diseases drug market is segmented into five regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. These regions have been further segmented by countries, disease type, and therapy class and distribution channel. North America dominated the market and is anticipated to gain more market share by the end of 2025. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global sexually transmitted diseases (STDs) drug market.

Companies Mentioned in Report

The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major companies competing in the global sexually transmitted diseases drug market, and profiled in the report include Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb Co. AbbVie, Inc., Gilead Sciences, GlaxoSmithKline Plc, and Merck & Co., Inc.

Sexually Transmitted Diseases (STDs) Drug Market is segmented as below:

Sexually Transmitted Diseases (STDs) Drug Market, by Disease Type

Chlamydia
Gonorrhea
Syphilis
Genital herpes
HPV
HIV/AIDS
Others
Sexually Transmitted Diseases (STDs) Drug Market, by Therapy Class

Antibiotics
Antiviral/Antiretrovirals
Vaccines
Others
Sexually Transmitted Diseases (STDs) Drug Market, by Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Sexually Transmitted Diseases (STDs) Drug Market, by Geography

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Research Approach & Methodology

3. Executive Summary

4. Market Definition
4.1. Introduction
4.1.1. Disease Definition
4.1.2. Industry Evolution / Developments
4.2. Market Overview
4.3. Key Market Conferences
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Key Trends
4.5. Global STDs Drug Market Revenue (US$ Mn) Forecast, 2017–2025
4.5.1. Market Revenue Projections (US$ Mn)
4.7. Porter’s Five Force Analysis
4.8. Market Outlook

5. Global STDs Drug Market Analysis, by Disease Type
5.1. Introduction & Definition
5.2. Key Findings / Developments
5.3. Market Size (US$ Mn) Forecast By Disease Type
5.3.1. Chlamydia
5.3.2. Gonorrhea
5.3.3. Syphilis
5.3.4. Genital herpes
5.3.5. HPV
5.3.6. HIV/AIDS
5.3.7. Others
5.4 Global STDs Drug Market Attractiveness Analysis, by Disease Type

6. Global STDs Drug Market Analysis and Forecast, By Therapy Class
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Size (US$ Mn) Forecast, By Therapy Class
6.3.1. Antibiotics
6.3.2. Antiviral/Antiretrovirals
6.3.3. Vaccines
6.3.4. Others
6.4. Market Attractiveness By Application

7. Global STDs Drug Market Analysis and Forecast, By Distribution Channel
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Size (US$ Mn) Forecast, By Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.3.4. Others
7.4. Market Attractiveness By Distribution Channel

8. Global STDs Drug Market Analysis and Forecast, By Region
8.1. Key Findings
8.2. Market Size (US$ Mn) Forecast By Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness By Country/Region

9. North America STDs Drug Market Analysis and Forecast
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Size (US$ Mn) Forecast By Disease Type
9.3.1. Chlamydia
9.3.2. Gonorrhea
9.3.3. Syphilis
9.3.4. Genital herpes
9.3.5. HPV
9.3.6. HIV/AIDS
9.3.7. Others
9.4. Market Attractiveness Analysis, by Disease Type
9.5. Market Size (US$ Mn) Forecast, By Therapy Class
9.5.1. Antibiotics
9.5.2. Antiviral/Antiretrovirals
9.5.3. Vaccines
9.5.4. Others
9.6 Market Attractiveness By Therapy Class
9.7. Market Size (US$ Mn) Forecast, By Distribution Channel
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
9.7.4. Others
9.8. Market Attractiveness By Distribution Channel
9.9. Market Size (US$ Mn) Forecast By Country
9.9.1. United State
9.9.2. Canada
9.10. Market Attractiveness By Country

10. Europe STDs Drug Market Analysis and Forecast
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Size (US$ Mn) Forecast By Disease Type
10.3.1. Chlamydia
10.3.2. Gonorrhea
10.3.3. Syphilis
10.3.4. Genital herpes
10.3.5. HPV
10.3.6. HIV/AIDS
10.3.7. Others
10.4. Market Attractiveness Analysis, by Disease Type
10.5. Market Size (US$ Mn) Forecast, By Therapy Class
10.5.1. Antibiotics
10.5.2. Antiviral/Antiretrovirals
10.5.3. Vaccines
10.5.4. Others
10.6 Market Attractiveness By Therapy Class
10.7. Market Size (US$ Mn) Forecast, By Distribution Channel
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
10.7.4. Others
10.8. Market Attractiveness By Distribution Channel
10.9. Market Size (US$ Mn) Forecast By Country
10.9.1. Germany
10.9.2. U.K.
10.9.3. France
10.9.4. Italy
10.9.5. Spain
10.9.6. Rest of Europe
10.10. Market Attractiveness By Country

11. Asia Pacific STDs Drug Market Analysis and Forecast
11.1. Introduction & Definition
11.2. Key Findings / Developments
11.3. Market Size (US$ Mn) Forecast By Disease Type
11.3.1. Chlamydia
11.3.2. Gonorrhea
11.3.3. Syphilis
11.3.4. Genital herpes
11.3.5. HPV
11.3.6. HIV/AIDS
11.3.7. Others
11.4. Market Attractiveness Analysis, by Disease Type
11.5. Market Size (US$ Mn) Forecast, By Therapy Class
11.5.1. Antibiotics
11.5.2. Antiviral/Antiretrovirals
11.5.3. Vaccines
11.5.4. Others
11.6 Market Attractiveness By Therapy Class
11.7. Market Size (US$ Mn) Forecast, By Distribution Channel
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
11.7.4. Others
11.8. Market Attractiveness By Distribution Channel
11.9. Market Size (US$ Mn) Forecast By Country
11.9.1. China
11.9.2. India
11.9.3. Japan
11.9.4. Australia & New Zealand
11.9.5. Rest of APAC
11.10. Market Attractiveness By Country

12. Latin America STDs Drug Market Analysis and Forecast
12.1. Introduction & Definition
12.2. Key Findings / Developments
12.3. Market Size (US$ Mn) Forecast By Disease Type
12.3.1. Chlamydia
12.3.2. Gonorrhea
12.3.3. Syphilis
12.3.4. Genital herpes
12.3.5. HPV
12.3.6. HIV/AIDS
12.3.7. Others
12.4. Market Attractiveness Analysis, by Disease Type
12.5. Market Size (US$ Mn) Forecast, By Therapy Class
12.5.1. Antibiotics
12.5.2. Antiviral/Antiretrovirals
12.5.3. Vaccines
12.5.4. Others
12.6 Market Attractiveness By Therapy Class
12.7. Market Size (US$ Mn) Forecast, By Distribution Channel
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
12.7.4. Others
12.8. Market Attractiveness By Distribution Channel
12.9. Market Size (US$ Mn) Forecast By Country
12.9.1. Brazil
12.9.2. Mexico
12.9.3. Rest of LATAM
12.10. Market Attractiveness By Country

13. Middle East & Africa STDs Drug Market Analysis and Forecast
13.1. Introduction & Definition
13.2. Key Findings / Developments
13.3. Market Size (US$ Mn) Forecast By Disease Type
13.3.1. Chlamydia
13.3.2. Gonorrhea
13.3.3. Syphilis
13.3.4. Genital herpes
13.3.5. HPV
13.3.6. HIV/AIDS
13.3.7. Others
13.4. Market Attractiveness Analysis, by Disease Type
13.5. Market Size (US$ Mn) Forecast, By Therapy Class
13.5.1. Antibiotics
13.5.2. Antiviral/Antiretrovirals
13.5.3. Vaccines
13.5.4. Others
13.6 Market Attractiveness By Therapy Class
13.7. Market Size (US$ Mn) Forecast, By Distribution Channel
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
13.7.4. Others
13.8. Market Attractiveness By Distribution Channel
13.9. Market Size (US$ Mn) Forecast By Country
13.9.1. GCC Countries
13.9.2. S. Africa
13.9.3. Israel
13.9.4. Rest of MEA
13.10. Market Attractiveness By Country

14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. Gilead Sciences, Inc.
14.2.1.1 Company Overview
14.2.1.2 Product Portfolio
14.2.1.3 SWOT Analysis
14.2.1.4 Strategic Overview
14.2.2. GlaxoSmithKline plc
14.2.2.1 Company Overview
14.2.2.2 Product Portfolio
14.2.2.3 SWOT Analysis
14.2.2.4 Strategic Overview
14.2.3. Merck & Co., Inc.
14.2.3.1 Company Overview
14.2.3.2 Product Portfolio
14.2.3.3 SWOT Analysis
14.2.3.4 Strategic Overview
14.2.4. Johnson & Johnson
14.2.4.1 Company Overview
14.2.4.2 Product Portfolio
14.2.4.3 SWOT Analysis
14.2.4.4 Strategic Overview
14.2.5. F. Hoffmann-La Roche Ltd.
14.2.5.1 Company Overview
14.2.5.2 Product Portfolio
14.2.5.3 SWOT Analysis
14.2.5.4 Strategic Overview
14.2.6. Teva Pharmaceutical Industries Ltd.
14.2.6.1 Company Overview
14.2.6.2 Product Portfolio
14.2.6.3 SWOT Analysis
14.2.6.4 Strategic Overview
14.2.7. Pfizer, Inc.
14.2.7.1 Company Overview
14.2.7.2 Product Portfolio
14.2.7.3 SWOT Analysis
14.2.7.4 Strategic Overview
14.2.8. Eli Lilly and Company
14.2.8.1 Company Overview
14.2.8.2 Product Portfolio
14.2.8.3 SWOT Analysis
14.2.8.4 Strategic Overview
14.2.9. Bristol-Myers Squibb Company
14.2.9.1 Company Overview
14.2.9.2 Product Portfolio
14.2.9.3 SWOT Analysis
14.2.9.4 Strategic Overview
14.2.10. AbbVie, Inc.
14.2.10.1 Company Overview
14.2.10.2 Product Portfolio
14.2.10.3 SWOT Analysis
14.2.10.4 Strategic Overview
14.2.11. Bayer AG
14.2.11.1 Company Overview
14.2.11.2 Product Portfolio
14.2.11.3 SWOT Analysis
14.2.11.4 Strategic Overview

List of Tables

Table 01 : Top Ten Countries With Highest Sexually Transmitted Disease Prevalence Globally
Table 02: Top Ten Developed Countries With the Highest STD Rates (Chlamydia, Gonorrhea and Syphilis)
Table 03: Global and regional estimates of the number of prevalent cases (‘000) in 2012 by infection and sex
Table 04: Percentage of population (%) with prevalent infection in 2012 by infection and sex (95% uncertainty interval shown in parentheses)
Table 05: Global and regional estimates of the number of incident cases (‘000) in 2012 by infection and sex
Table 06: Incidence rates (per 1,000) by infection and sex, based on 2005 to 2012 data (95% uncertainty interval shown in parentheses)
Table 07: HIV-AIDS Prevalence by Region Wise
Table 08: Top Ten Countries People Living With HIV-AIDS in 2016
Table 09: Sexually Transmitted Diseases — Reported Cases and Rates of Reported Cases per 100,000 Population, United States, 2010–2015
Table 10: Upcoming STDs Conferences with Date and Locations
Table 11: Global STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 12: Global STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 13: Global STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 14: Global STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 15: North America STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 16: North America STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 17: North America STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 18: North America STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 19: Europe STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 20: Europe STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 22: Europe STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 24: Europe STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 25: Asia Pacific STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 26: Asia Pacific STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 27: Asia Pacific STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 28: Asia Pacific STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 29: Latin America STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 30: Latin America STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 31: Latin America STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 32: Latin America STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 33: Middle East & Africa STDs Drug Market Size (US$ Mn) Forecast, by Disease Type, 2015–2025
Table 34: Middle East & Africa STDs Drug Market Size (US$ Mn) Forecast, by Therapy Class, 2015–2025
Table 35: Middle East & Africa STDs Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 36: Middle East & Africa STDs Drug Market Size (US$ Mn) Forecast, by Region, 2015–2025